
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$41.10
+US$1.85 · +4.71%
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
前收盤價
US$41.10
+US$1.85 · +4.71%
盤中時間採用ET。市場資料可能有所延遲。
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
日內區間
目前US$41.10
52週區間
目前US$41.10
盤中時間採用ET。市場資料可能有所延遲。
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
日內區間
目前US$41.10
52週區間
目前US$41.10
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 172.57億 USD | 165.44億 USD | 158.45億 USD | 149.25億 USD | 158.78億 USD |
| 銷貨成本 | 83.2億 USD | 84.81億 USD | 82億 USD | 79.52億 USD | 82.84億 USD |
| 毛利 | 89.38億 USD | 80.63億 USD | 76.45億 USD | 69.73億 USD | 75.94億 USD |
| 研究與開發 | 10.13億 USD | 10.55億 USD | 9.53億 USD | 8.38億 USD | 10.94億 USD |
| 銷售、一般及管理費用 | 39.73億 USD | 37.02億 USD | 34.98億 USD | 34.45億 USD | 35.28億 USD |
| 營業費用 | 67.8億 USD | 83.66億 USD | 72.12億 USD | 91.7億 USD | 58.78億 USD |
| 利息收入 | — | — | 6800萬 USD | — | — |
| 利息支出 | 9.16億 USD | 9.41億 USD | 10.29億 USD | 9.3億 USD | 8.91億 USD |
| 折舊和攤銷 | 10.02億 USD | 10.59億 USD | 11.53億 USD | 13.08億 USD | 13.3億 USD |
| 營業利益 | 21.57億 USD | −3.03億 USD | 4.33億 USD | −21.97億 USD | 17.16億 USD |
| 淨利 | 14.1億 USD | −16.39億 USD | −5.59億 USD | −24.46億 USD | 4.17億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2004年7月1日 | 2:1 | — | — |
股票分割 | 2002年12月6日 | 2:1 | — | — |
股票分割 | 2000年2月23日 | 2:1 | — | — |
股票分割 | 1993年4月14日 | 2:1 | — | — |
股票分割 | 1982年8月16日 | 7:5 | — | — |
已生效 2004年7月1日
2:1
已生效 2002年12月6日
2:1
已生效 2000年2月23日
2:1
已生效 1993年4月14日
2:1
已生效 1982年8月16日
7:5
報告持有此股票曝險的交易所交易基金。
iShares Core MSCI EAFE ETFIEFA3.48億0.19%1894.71億 USD0.07%US$96.52+0.68%
iShares MSCI EAFE ETFEFA1.64億0.22%765.34億 USD0.32%US$103.4+0.68%
Schwab International Equity ETFSCHF1.04億0.15%674.08億 USD0.03%US$27.27+0.66%
iShares MSCI Israel ETFEIS9841.45萬11.49%8.6億 USD0.59%US$118.28+0.54%
First Trust WCM International Equity ETFWCMI7978.94萬3.81%20.87億 USD0.85%US$19.05+1.06%
iShares MSCI EAFE Growth ETFEFG6494.18萬0.44%150.87億 USD0.34%US$120.3+1.05%
iShares Core MSCI Total International Stock ETFIXUS6320.6萬0.11%586.25億 USD0.07%US$94.99+0.90%
iShares Core MSCI International Developed Markets ETFIDEV5496.97萬0.17%331.28億 USD0.04%US$89.21+0.73%
iShares Core MSCI EAFE ETFIEFA
iShares MSCI EAFE ETFEFA
Schwab International Equity ETFSCHF
iShares MSCI Israel ETFEIS
First Trust WCM International Equity ETFWCMI
iShares MSCI EAFE Growth ETFEFG
iShares Core MSCI Total International Stock ETFIXUS
iShares Core MSCI International Developed Markets ETFIDEVAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。